19 May 2013
Keywords: americans, understand, rx, risk/benefits, study, consumers, response
Article | 14 March 2005
US consumers' response to concerns relating to the COX-2 inhibitors - Pfizer's Celebrex (celebrex) and Bextra (valdecoxib) and Merck & Co's
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
14 March 2005
28 February 2005
17 May 2013
© 2013 thepharmaletter.com